Literature DB >> 19265199

The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.

Jianmin Sun1, Malin Pedersen, Lars Rönnstrand.   

Abstract

The receptor tyrosine kinase c-Kit plays a critical role in hematopoiesis, and gain-of-function mutations of the receptor are frequently seen in several malignancies, including acute myeloid leukemia, gastrointestinal stromal tumors, and testicular carcinoma. The most common mutation of c-Kit in these disorders is a substitution of the aspartic acid residue in position 816 to a valine (D816V), leading to constitutive activation of the receptor. In this study, we aimed to investigate the role of Src family kinases in c-Kit/D816V signaling. Src family kinases are necessary for the phosphorylation of wild-type c-Kit as well as of activation of downstream signaling pathways including receptor ubiquitination and the Ras/Mek/Erk pathway. Our data demonstrate that, unlike wild-type c-Kit, the phosphorylation of c-Kit/D816V is not dependent on Src family kinases. In addition, we found that neither receptor ubiquitination nor Erk activation by c-Kit/D816V required activation of Src family kinases. In vitro kinase assay using synthetic peptides revealed that c-Kit/D816V had an altered substrate specificity resembling Src and Abl tyrosine kinases. We further present evidence that, in contrast to wild-type c-Kit, Src family kinases are dispensable for c-Kit/D816V cell survival, proliferation, and colony formation. Taken together, we demonstrate that the signal transduction pathways mediated by c-Kit/D816V are markedly different from those activated by wild-type c-Kit and that altered substrate specificity of c-Kit circumvents a need for Src family kinases in signaling of growth and survival, thereby contributing to the transforming potential of c-Kit/D816V.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265199      PMCID: PMC2670109          DOI: 10.1074/jbc.M808058200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

Authors:  Marcus M Schittenhelm; Sharon Shiraga; Arin Schroeder; Amie S Corbin; Diana Griffith; Francis Y Lee; Carsten Bokemeyer; Michael W N Deininger; Brian J Druker; Michael C Heinrich
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 2.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

Review 3.  Negative regulation of PTK signalling by Cbl proteins.

Authors:  Christine B F Thien; Wallace Y Langdon
Journal:  Growth Factors       Date:  2005-06       Impact factor: 2.511

4.  Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

Authors:  Zhifu Xiang; Frederike Kreisel; Jennifer Cain; AnnaLynn Colson; Michael H Tomasson
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

5.  Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation.

Authors:  Kristina Masson; Elke Heiss; Hamid Band; Lars Rönnstrand
Journal:  Biochem J       Date:  2006-10-01       Impact factor: 3.857

6.  Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.

Authors:  R Chian; S Young; A Danilkovitch-Miagkova; L Rönnstrand; E Leonard; P Ferrao; L Ashman; D Linnekin
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

7.  Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction.

Authors:  J Lennartsson; P Blume-Jensen; M Hermanson; E Pontén; M Carlberg; L Rönnstrand
Journal:  Oncogene       Date:  1999-09-30       Impact factor: 9.867

8.  Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl).

Authors:  Shan Zeng; Zhiheng Xu; Stan Lipkowitz; Jack B Longley
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

9.  c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study.

Authors:  Katharina Pauls; Eva Wardelmann; Sabine Merkelbach-Bruse; Reinhard Büttner; Hui Zhou
Journal:  Virchows Arch       Date:  2004-09-29       Impact factor: 4.064

Review 10.  The stem cell factor receptor/c-Kit as a drug target in cancer.

Authors:  J Lennartsson; L Rönnstrand
Journal:  Curr Cancer Drug Targets       Date:  2006-02       Impact factor: 3.428

View more
  22 in total

Review 1.  Mast cell homeostasis and the JAK-STAT pathway.

Authors:  J K Morales; Y T Falanga; A Depcrynski; J Fernando; J J Ryan
Journal:  Genes Immun       Date:  2010-06-10       Impact factor: 2.676

2.  Gene networks in basal cell carcinoma of the eyelid, analyzed using gene expression profiling.

Authors:  Tatsuya Yunoki; Yoshiaki Tabuchi; Tetsushi Hirano; Shigeharu Miwa; Johji Imura; Atsushi Hayashi
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

3.  PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.

Authors:  Oscar Lindblad; Julhash U Kazi; Lars Rönnstrand; Jianmin Sun
Journal:  Cell Mol Life Sci       Date:  2015-06-04       Impact factor: 9.261

4.  Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild-type and mutant forms of KIT.

Authors:  Sabrina Brahimi-Adouane; Jean-Baptiste Bachet; Séverine Tabone-Eglinger; Frédéric Subra; Claude Capron; Jean-Yves Blay; Jean-François Emile
Journal:  Mol Oncol       Date:  2012-10-30       Impact factor: 6.603

5.  Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation.

Authors:  Shruti Agarwal; Julhash U Kazi; Lars Rönnstrand
Journal:  J Biol Chem       Date:  2013-06-26       Impact factor: 5.157

Review 6.  Molecular response prediction in gastrointestinal stromal tumors.

Authors:  Philippe A Cassier; Jean-Yves Blay
Journal:  Target Oncol       Date:  2010-04-02       Impact factor: 4.493

7.  The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.

Authors:  Laura A Noël; Florence A Arts; Carmen P Montano-Almendras; Luk Cox; Olga Gielen; Federica Toffalini; Catherine Y Marbehant; Jan Cools; Jean-Baptiste Demoulin
Journal:  Mol Oncol       Date:  2014-02-17       Impact factor: 6.603

8.  The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.

Authors:  Erola Ainsua-Enrich; Eva Serrano-Candelas; Damiana Álvarez-Errico; César Picado; Joan Sayós; Juan Rivera; Margarita Martín
Journal:  J Immunol       Date:  2015-03-25       Impact factor: 5.422

9.  The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Authors:  S Agarwal; J U Kazi; S Mohlin; S Påhlman; L Rönnstrand
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

10.  A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.

Authors:  Daniel Smrž; Geethani Bandara; Shuling Zhang; Beverly A Mock; Michael A Beaven; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Immunol Methods       Date:  2013-01-25       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.